Skip to main content
SpringerLink
Log in

Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

The antipsychotic drug risperidone shows high affinity for both central serotonin (5-HT)2A and dopamine (DA)-D2 receptors in vivo. By employing microdialysis in freely moving rats, the effects of acute risperidone administration on regional brain DA and 5-HT release and metabolism were compared with the corresponding effects of the atypical antipsychotic drug clozapine as well as amperozide, the selective DA-D2 receptor antagonist raclopride and the selective 5-HT2A/5-HT2C receptor antagonist ritanserin. Risperidone (0.2 or 2.0 mg/kg, SC) was found to increase DA release and metabolism to about the same extent in three major projection areas of the mesotelencephalic dopaminergic system, i.e. the nucleus accumbens (NAC), the medial prefrontal cortex (MPC) and the lateral striatum (STR). In contrast, clozapine and amperozide (both 10.0 mg/kg, SC), as well as raclopride (2.0 mg/kg, SC), were all found differentially to affect DA release and metabolism in the three projections areas. Specifically, clozapine and amperozide enhanced DA release in the MPC to a greater extent than in the NAC or the STR, whereas raclopride instead preferentially increased DA release in the NAC and the STR but not in the MPC. Ritanserin (3.0 mg/kg, SC) did not exert any major effects on DA metabolism in the three areas studied. In contrast to the regionally rather homogenous activation of brain DA systems caused by risperidone, the drug was found to enhance brain 5-HT metabolism preferentially in the MPC, as indicated by the elevated extracellular concentration of 5-hydroxyindoleacetic acid (5-HIAA) in this region. A similar elevation of the 5-HIAA level in the MPC was observed after amperozide and, to some extent, after clozapine and ritanserin administration. The risperidone-induced (2.0 mg/kg, SC) elevation of 5-HIAA concentrations in the frontal cortex was found to be paralleled by an increased 5-HT release in this brain area. Consequently, our findings demonstrate a pharmacological profile of risperidone, as reflected in brain DA metabolism, in between that of clozapine and the DA-D2 antagonists. The preferential activation of 5-HT release and metabolism in frontal cortical areas might be of particular relevance for the ameliorating effect of risperidone on negative symptoms in schizophrenia, especially when associated with depression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Altar CA, Wasjey AM, Neale RF, Stone GE (1986) Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradographic analysis in rat brain. Brain Res Bull 16:517–525

    Google Scholar 

  • Andén NE, Stock G (1973) Effects of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system. J Pharm Pharmacol 25:346–348

    Google Scholar 

  • Andersson JL, Nomikos GG, Marcus M, Hertel P, Mathé JM, Svensson TH (1995) Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system. Naunyn Schmiedeberg's Arch Pharmacol 352:374–385

    Google Scholar 

  • Ashby CR, Wang RY (1990) Effects of antipsychotic drugs on 5-HT2 receptors in the medial prefrontal cortex: microiontophoretic studies. Brain Res 506:346–348

    Google Scholar 

  • Axelsson R, Nilsson A, Christensson E, Björk A (1991) Effects of amperozide in schizophrenia. Psychopharmacology 104:287–292

    Google Scholar 

  • Bartholini G (1976) Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic systems. J Pharm Pharmacol 28:429–433

    Google Scholar 

  • Baxter G, Kennett G, Blaney F, Blackburn T (1995) 5-HT2 receptor subtypes: a family re-united? Trends Pharmacol Sci 16:105–110

    Google Scholar 

  • Berman KF, Weinberger DR (1990) Prefrontal dopamine and defect symptoms in schizophrenia. In: Greden JF, Tandon R (eds) Negative schizophrenic symptoms: pathophysiology and clinical implications (Progress in Psychiatry Series vol. 28). American Psychiatric Press, Washington, DC, London, England, pp 81–95

    Google Scholar 

  • Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N (1986) Neuroleptic-induced extrapyramidal side-effects: clinical perspectives with ritanserin (R55 667), a new selective 5-HT2 receptor blocking agent. Curr Ther Res 40:492–499

    Google Scholar 

  • Björk A, Bergman I, Gustavsson G (1992) Amperozide in treatment of schizophrenic patients. A preliminary report. In: Meltzer HY (ed) Novel antipsychotic drugs. Raven Press, New York, pp 47–57

    Google Scholar 

  • Borison RL, Parhiraja PA, Diamond BI, Meibach RC (1992) Risperidone: clinical satfey and efficacy in schizophrenia. Psychopharmacol Bull 28:213–218

    Google Scholar 

  • Carboni E, Di Chiara G (1989) Serotonin release estimated by transcortical dialysis in freely moving animals. Neuroscience 32:637–645

    Google Scholar 

  • Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopoaminergic neurons. J Neurosci 3:1607–1619

    Google Scholar 

  • Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25–40

    Google Scholar 

  • Claghorn J, Honigfeld G, Abuzzahab FS, Wans R, Steinbook R, Tuason V, Klerman G (1987) The risk and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7:377–384

    Google Scholar 

  • Coward DM (1992) General pharmacology of clozapine. Br J Psychiatry 160 [Suppl 17]:5–11

    Google Scholar 

  • De Boer T, Netkens F, Helvoirt A (1994) The α2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo. Eur J Pharmacol 253: R5-R6

    Google Scholar 

  • Deutch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, Charney DS (1991) Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schizophr Res 4:121–156

    Google Scholar 

  • Devaud LL, Hollingsworth EB, Cooper BR (1992) Alteration in extracellular and tissue levels of biogenic amines in rat brain induced by the serotonin2 receptor antagonist, ritanserin. J Neurochem 59:1459–1466

    Google Scholar 

  • Farde L, Nordström A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538–544

    Google Scholar 

  • Ferré S, Artigas F (1995) Clozapine decreases serotonin extracellular levels in the nucleus accumbens by a dopamine receptor-independent mechanism. Neurosci Lett 187:61–64

    Google Scholar 

  • Fink H, Morgenstern R, Oetssner W (1984) Clozapine — a serotonin antagonist? Pharmacol Biochem Behav 20:513–517

    Google Scholar 

  • Fitton A, Heel RC (1990) Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40 [5]:722–747

    Google Scholar 

  • Gelders YG (1989) Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br J Psychiatry 155:33–36

    Google Scholar 

  • Gelders YG, VandenBussche G, Reyntjens A, Janssen P (1986) Serotonin-S2 receptor blockers in the treatment of chronic schizophrenia. Clin Neuropharmacol 9:327–327

    Google Scholar 

  • Gellman RL, Aghajanian GK (1994) Serotonin2 receptor-mediated excitation of interneurons in piriform cortex: antagonism by atypical antipsychotic drugs. Neuroscience 58:515–525

    Google Scholar 

  • Grenhoff J, Tung C-S, Ugedo L, Svensson TH (1990) Effects of amperozide, a putative antipsychotic drug, on rat midbrain dopamine neurons recorded in vivo. Pharmacol Toxicol 66 [suppl 1]:29–33

    Google Scholar 

  • Hand TH, HU X-T, Wang RY (1987) Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons. Brain Res 415:257–269

    Google Scholar 

  • Hillert A, Maier W, Wetzel H, Benkert O (1992) Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome — a functional approach. Pharmacopsychiatry 25:213–217

    Google Scholar 

  • Ingvar DH (1987) Evidence for frontal/prefrontal cortical dysfunction in chronic schizophrenia: the phenomenon of hypofrontality reconsidered. In: Helmchen H, Henn FA (eds) Biological perspectives of schizophrenia. Wiley, New York, pp 201–211

    Google Scholar 

  • Janssen PAJ, Niemegeers CJE, Awouters F, Schellekens KHL, Megens AAHP, Meert TF (1988) Pharmacology of risperidone (R 64766), a new antipsychotic drug with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244:685–693

    Google Scholar 

  • Kahn RS, Davis KL (1995) New developments in dopamine and schizophrenia. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York, pp 1193–1203

    Google Scholar 

  • Kane J, Honigteld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789–796

    Google Scholar 

  • Krupp P, Barnes P (1992) Clozapine-associated agranulocytosis: risk and aetiology. Br J Psychiatry 160 [Suppl 17]:38–40

    Google Scholar 

  • Leysen JE, Commeron W, Van Gompel P, Wynants J, Janssen PFM, Laduron PM (1985) Receptor-binding properties in vitro and in vivo of ritanserin. A very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 27:600–611

    Google Scholar 

  • Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ (1988) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661–670

    Google Scholar 

  • Leysen JE, Janssen PMF, Gommeren W, Wynants J, Pauwels PJ, Janssen PAJ (1992) In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 41:494–508

    Google Scholar 

  • Leysen JE, Janssen PMF, Schotte A, Luyten WHML, Megens AAHP (1993) Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology 112:S40-S54

    Google Scholar 

  • Lindström E, Von Knorring L (1993) Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol. Pharmacopsychiatry 27:108–113

    Google Scholar 

  • Maidment NT, Marsden CA (1987) Acute administration of clozapine, thioridazine and metoclopramide increases extracellular DOPAC and decreases extracellular 5-HIAA, measured in the nucleus accumbens and striatum of the rat using in vivo voltammetry. Neuropharmacology 26:187–193

    Google Scholar 

  • Mantz J, Godout R, Tassin J-P, Glowinski J, Thierry A-M (1990) Inhibition of spontaneous and evoked unit activity in the rat medial prefrontal cortex by mesencephalic raphe nuclei. Brain Res 524:22–30

    Google Scholar 

  • Matsubara S, Matsubara R, Kusumi I, Koyama T, Yamashita I (1993) Dopamine D1, D2 and serotonin2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J Pharmacol Exp Ther 265:498–508

    Google Scholar 

  • Meltzer HY, Nash JF (1991) Effects of antipsychotic drugs on seroronin receptors. Pharmacol Rev 43:587–604

    Google Scholar 

  • Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238–246

    Google Scholar 

  • Meltzer HY, Zhang Y, Stockmeier CA (1992) Effect of amperozide on rat cortical 5-HT2 and striatal and limbic dopamine D2 receptor occupancy: implications for antipsychotic action. Eur J Pharmacol 216:67–71

    Google Scholar 

  • Mesotten F, Suy E, Pietquin M, Burton P, Heylen S (1989) Therapeutic effect and saftey of increasing dose of risperidone (R64744) in psychotic patients. Psychopharmacology 99:445–449

    Google Scholar 

  • Moghaddam B, Bunney BS (1990a) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54:1755–1760

    Google Scholar 

  • Moghaddam B, Bunney BS (1990b) Utilization of microdialysis for assessing the release of mesotelencephalic dopamine following clozapine and other antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry 14:S51-S57

    Google Scholar 

  • Nomikos GG, Damsma G, Wenkstern D, Fibiger HC (1992) Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum. Neuropsychopharmacology 7:7–14

    Google Scholar 

  • Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH (1994) Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology 115:147–156

    Google Scholar 

  • Owens DGC (1994) Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 55 [suppl 5]: 29–35

    Google Scholar 

  • Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic Press, London

    Google Scholar 

  • Pazos A, Cortés R, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 346:231–249

    Google Scholar 

  • Pehek AA, Meltzer HY, Yamamoto BK (1993) The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux. Eur J Pharmacol 240: 107–109

    Google Scholar 

  • Robertson GS, Matsumura H, Fibiger HC (1994) Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271:1058–1066

    Google Scholar 

  • Schotte A, Janssen PFM, Megens AAHP, Leysen JE (1993) Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 631:191–202

    Google Scholar 

  • Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32:229–313

    Google Scholar 

  • Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717–719

    Google Scholar 

  • Sorensen SM, Kehne JH, Fadayel GM, Humphreys TM, Ketteler HJ, Sullivan CK, Taylor VL, Schmidt CJ (1993) Characterization of the 5-HT2 antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266: 684–691

    Google Scholar 

  • Sumiyoshi T, Kido H, Sakamoto H, Urasaki K, Suzuki K, Yamaguchi N, Mori H, Shiba K, Yokogawa K (1994) In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol. Pharmacol Biochem Behav 47:553–557

    Google Scholar 

  • Sumiyoshi T, Suzuki K, Sakamoto H, Yamaguchi N, Hirofumi M, Shiba K, Yokogawa K (1995) Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5-HT2 receptor occupancy. Neuropsychopharmacology 12:57–64

    Google Scholar 

  • Svartengren J, Celander M (1994) The limbic functional selectivity of amperozide is not mediated by dopamine D2 receptors as assessed by in vitro and in vivo binding. Eur J Pharmacol 254:73–81

    Google Scholar 

  • Svartengren J, Simonsson P (1990) Receptor binding properties of amperozide. Pharmacol Toxicol 66 [Suppl 1]:8–11

    Google Scholar 

  • Svensson TH, Bunney BS, Aghajanian GK (1975) Inhibition of both noradrenergic and serotonergic neurons in brain by the α-adrenergic agonist clonidine. Brain Res 92:291–306

    Google Scholar 

  • Svensson TH, Tung C-S, Grenhoff J (1989) The 5-HT2 antagonist ritanserin blocks the effect of pre-frontal cortex inactivation on rat A10 dopamine neurons in vivo. Acta Physiol Scand 136:497–498

    Google Scholar 

  • Svensson TH, Nomikos GG, Andersson JL (1993) Modulation of dopaminergic neurotransmission by 5-HT2 antagonism. In: Vanhoutte PM, Saxena PR, Paoletti R, Brunello N, Jackson AS (eds) Serotonin. Kluwer Academic Publisher Dordrecht, and Fondazione Lorenzini, Milan, pp 263–270

    Google Scholar 

  • Svensson TH, Mathé JM, Andersson JL, Nomikos GG, Hildebrand BE, Marcus M (1995) Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and α1-adrenoceptor antagonism. J Clin Psychopharmacol 15 [Suppl 1]: 11–18

    Google Scholar 

  • Ugedo L, Grenhoff J, Svensson TH (1989) Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98:45–50

    Google Scholar 

  • Vandermaelen CP, Aghajanian GK (1983) Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly in rat brain slices. Brain Res 289:109–119

    Google Scholar 

  • Van Wielinck PS, Leysen JE (1983) Choise of neuroleptics based on in vitro pharmacology. J Drug Res 8:1984–1997

    Google Scholar 

  • Weinberger DF (1987) Implications of normal brain development for the pathogenesis of Schizophrenia. Arch Gen Psychiatry 44:660–669

    Google Scholar 

  • White FJ, Wang RY (1983) Differential effect of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054–1055

    Google Scholar 

  • Wright IK, Gariat JC, Marsden CA (1990) Effects of a selective 5-HT2 agonist, DOI, on 5-HT neuronal firing in the dorsal raphe necleus and 5-HT release and metabolism in the frontal cortex. Br J Pharmacol 99:221–222

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Physiology and Pharmacology, Division of Pharmacology, Karolinska Institutet, S-171 77, Stockholm, Sweden

    P. Hertel, G. G. Nomikos, M. Iurlo & T. H. Svensson

Authors
  1. P. Hertel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. G. Nomikos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Iurlo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. H. Svensson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hertel, P., Nomikos, G.G., Iurlo, M. et al. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology 124, 74–86 (1996). https://doi.org/10.1007/BF02245607

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02245607

Key words

Search

Navigation